Mike Tyson Unveils New Cannabis Brand in New York

Business by 2FIRSTS.ai
Jan.22.2024
Mike Tyson Unveils New Cannabis Brand in New York
Hundreds of Mike Tyson fans lined up outside a New York pharmacy to support his new marijuana business venture.

According to a recent report by The New York Times, hundreds of followers of Mike Tyson, one of the greatest boxers of all time, lined up at a pharmacy in New York over the weekend in hopes of getting a chance to meet him and show support for his latest business venture: selling marijuana in his home state.

 

According to reports, 57-year-old Tyson has recently launched the Tyson 2.0 brand, emerging as one of the most notable newcomers in the New York cannabis industry. As the legalization of cannabis gradually spreads across the United States, actors, athletes, and musicians have been profiting from the marijuana industry through product lines and sponsorship contracts for over a decade. However, the trend has only recently started to gain momentum in New York. Tyson is seeking to test his fame and become a prominent figure in what is projected to become the world's largest and most competitive market.

 

The evaluations of cannabis brands backed by celebrities are mixed. While their sales often surpass those of traditional brands, they cannot compete with the biggest brand that sells millions of dollars worth of cannabis every month.

 

According to data from Headset, a specialized cannabis data company, out of the top 30 bestselling brands in California, the largest market in the United States, only 9 of them are owned or endorsed by celebrities. These include Tyson 2.0, actor Seth Rogen's Houseplant, and musician Carlos Santana's Mirayo.

 

One of the company analysts, Mitchell Laferla, noted that the ultimate driving factor for consumers in emerging markets like New York is value, and this is precisely where celebrity-endorsed brands face difficulties.

 

Consumers who spend lavishly are now seeking the most powerful features at the lowest prices, while the quality of celebrity brands varies, often commanding higher prices. In California, a bag of 3.5 grams typically sells for around $23.14, whereas Tyson 2.0 is priced at approximately $28.44, representing a 23% difference.

 

Lafra states that the success of Tyson 2.0 can be attributed to the way Tyson interacts with its clients and their companies, its proactive expansion into new markets such as New York and Maryland, and the quality of its products.

 

"Your name may entice someone to give it a try," he said. "But it's your brand and product quality that are the factors that keep people coming back."

 

Yuvraj Singh, the CEO of Long Island Strain Stars, has stated that customers have returned to purchase more cannabis from Tyson Foods. On the first day of the launch of their Tyson 2.0 flower line, their customers bought a total of $30,000 worth of cannabis products, making the cannabis series one of the top five best-selling products in the store.

 

According to reports, he described its effect as a highly pleasurable and refreshing sensation.

 

Coss Marte, co-owner and CEO of Conbud, has stated that their pharmacy has also attracted more customers to make purchases, selling $10,000 worth of Tyson 2.0 within an hour, which is equivalent to the pharmacy's typical daily sales.

 

Former boxing champion Mike Tyson has emphasized the therapeutic effects of marijuana in his transformation from an arrogant athlete to a disciplined businessman. In an interview, he revealed that less than a decade ago, he was penniless and struggling with a cocaine addiction. Today, he is the owner of one of the most successful celebrity marijuana brands in the country.

 

Tyson stated that his goal is to solidify his legacy as a pioneer of cannabis. "This is more important to me than making money," he declared.

 

Tyson was born into a financially disadvantaged family in Brooklyn and later discovered his boxing talent at a reform school in the north. He quickly became a teenage sensation and eventually won 50 professional matches, most of which were victories by knockout.

 

However, his reputation has been tarnished due to his antics, such as biting Hollyfield's ear, as well as his legal troubles, including a three-year prison sentence for a rape case that he still denies. In 2014, he revealed his dependency on cocaine and claimed that marijuana helped him break free from addiction. He currently resides in Las Vegas and owns a marijuana farm in California.

 

His personal story has attracted many fans, who seem eager to support him. "He has gone through some difficult times, and I can relate to that," said 26-year-old Tony Pedroza, a boxing enthusiast from Brooklyn who was standing in line in Manhattan to see Tyson.

 

Monifa Jones-Tuck and her husband, Troy Tuck, drove from Bethlehem, Pennsylvania to show their support for him. Jones expressed that they have been following Tyson's boxing career since the beginning and admire his progress.

 

"After using marijuana, his mind is currently in a good and calm state," he said. "It suits him well, and he also looks great."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30